#### **EsoDetect:** Computational Validation and Algorithm 1 **Development of a Novel Diagnostic and Prognostic Tool for** 2 **Dysplasia in Barrett's Esophagus** 3

- 5 Migla Miskinyte<sup>1</sup>, Benilde Pondeca<sup>1</sup>, José B. Pereira-Leal<sup>1</sup>, Joana Cardoso<sup>1</sup>
- 6 <sup>1</sup> Ophiomics, Lisbon, Portugal
- 7

4

- 8 Corresponding Author:
- 9 Joana Cardoso
- 10 R. António Champalimaud 1 Sala 14, 1600-514, Lisbon, Portugal
- 11 Email address: jvaz@ophiomics.com
- 12
- 13
- 14
- 15
- 16

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 17 ABSTRACT

Barrett's esophagus (BE) is the only known precursor to esophageal adenocarcinoma (EAC), a malignancy with increasing incidence and unfavorable prognosis. This study endeavors to identify BE biomarkers capable of diagnosing low-grade dysplasia (LGD) in BE, as well as biomarkers that can predict the progression from BE to EAC to be subsequently integrated into diagnostic and prognostic algorithms.

23 Datasets containing gene expression data from metaplastic and dysplastic BE, as well as EAC 24 tissue samples, were collected from public databases and used to explore gene expression 25 patterns that differentiate between non-dysplastic (ND) and LGD BE (for diagnostic purposes) 26 and between non-progressed and progressed BE (for prognostic purposes). Specifically, for the 27 diagnostic application, three RNAseq datasets were employed, while for the prognostic 28 application, nine microarray datasets were identified, and 25 previously described genes were 29 validated. A Thresholding Function was applied to each gene to determine the optimal gene 30 expression threshold for group differentiation. All analyzed genes were ranked based on the 31 F1-score metrics. Following the identification of genes with superior performance, different 32 classifiers were trained. Subsequently, the best algorithms for diagnostic and prognostic 33 applications were selected.

In evaluating the value of gene expression for diagnosis and prognosis, the analyzed datasets allowed for the ranking of biomarkers, resulting in eighteen diagnostic genes and fifteen prognostic genes that were used for further algorithm development. Ultimately, a linear support vector machine algorithm incorporating ten genes was identified for diagnostic application, while a radial basis function support vector machine algorithm, also utilizing ten genes, was selected for prognostic prediction. Notably, both classifiers achieved recall and specificity scores exceeding 0.90.

The identified algorithms, along with their associated biomarkers, hold significant potential to aid in the early management of malignant progression of BE. Their strengths lie in their development using multiple independent datasets and their ability to demonstrate recall and specificity levels superior to those reported in the existing literature. Ongoing experimental and clinical validation is essential to further substantiate their utility and effectiveness, and to ensure that these tools can be reliably integrated into clinical practice to improve patient outcomes.

49 KEYWORDS: Barrett's esophagus; Esophageal adenocarcinoma; Biomarkers, Diagnosis;
 50 Prognosis; Machine Learning

### 52 1. INTRODUCTION

53 Barrett's esophagus (BE) is characterized by the replacement of the normal squamous 54 epithelium lining the lower esophagus with specialized columnar cells (intestinal metaplasia) 55 [1–4]. This transformation occurs because of chronic gastroesophageal reflux disease (GERD) 56 [1, 2] and exposure to stomach acid [3]. Approximately 10% of patients with GERD are likely to 57 progress to a diagnosis of BE over 5 years [5]. Individuals with BE have a significantly increased 58 risk of developing esophageal adenocarcinoma (EAC). Typically, the progression of EAC starts 59 with GERD, followed by abnormal columnar cells characteristic of BE, which, over time, can 60 progress to dysplasia and eventually become EAC. Despite BE's role as a precursor to EAC, the 61 exact risk factors associated with BE are still not fully understood but include age ( $\geq$  60-70 62 years), male gender [6], tobacco use [7, 8], obesity [9], and hiatal hernia [10].

63 The clinical relevance of BE relies on its role as the sole known precursor lesion for EAC [1, 11]. 64 This specific type of esophageal cancer constitutes already around two-thirds of all cases of 65 esophageal cancer in high-income countries [12], with 85,700 new EAC cases estimated 66 worldwide in 2020. Over the next two decades, a staggering 65% increase (equivalent to 67 approximately 55,600 additional cases annually) is predicted [13]. EAC is a major problem 68 because of its association with poor survival rates, one of the lowest in oncology. Post-69 diagnosis, EAC presents a 23% 5-year survival and a median survival of only 15 months [14], 70 highlighting the need for efficient methods for EAC management. This low survival is mainly 71 due to late diagnosis, limited treatment options, poor prognosis, high rate of early metastasis, 72 and difficulties in early detection [15].

73 Due to the low progression rate of BE to EAC (estimates 0.1-0.5, reviewed by [16]), most BE 74 patients never progress to cancer. However, GERD is becoming increasingly prevalent, with a 75 global estimate of 783 million prevalent cases in 2019 [17]. Factors like population growth, aging, lifestyle changes, and improved living standards contribute to the rising incidence of
 GERD [18]. As BE is a complication of GERD and a significant risk factor for EAC, the increasing
 prevalence of GERD cases represents a menace to future management of EAC. The increased
 prevalence of GERD leads to a higher incidence of BE cases and pressures for BE screening and
 diagnosis, resulting in a significant economic burden for patients, families, health services, and
 society.

82 Currently, BE serves as a critical warning sign and its surveillance is essential for effective risk 83 stratification. BE screening and surveillance methods involve endoscopic sampling of biopsies 84 from four quadrants according to the Seattle biopsy protocol [19, 20] followed by histological 85 analysis to classify detectable BE lesions as non-dysplastic (NDBE), indefinite for dysplasia 86 (IND), low-grade dysplasia (LGD), or high-grade dysplasia (HGD) [11]. Limitations to the success 87 of current strategies include but are not limited to, difficulties with endoscopic identification 88 of dysplasia, biopsy sampling error, low interobserver reproducibility in histologic assessment 89 of dysplasia among pathologists, lack of reliable biomarkers, access to specialized care and 90 patient compliance [21]. Variability in the endoscopic and histologic assessment are commonly 91 known issues: BE endoscopic/pathological management is time-consuming and depends on 92 the clinical experience of the physicians involved in the endoscopic examination and/or 93 histological analysis – who are mostly available in BE reference centers. For example, one meta-94 analysis reported up to 25% and 24% of EACs were respectively missed during surveillance or 95 when the analysis was restricted to NDBE patients [22]. Regarding histological analysis, the 96 inter-observer agreement among pathologists has been reported as only 58% when it comes 97 to distinguishing normal esophagus from BE and was even lower (less than 50%) when 98 diagnosing LGD in BE patients [23, 24]. The lack of agreement can become particularly

99 problematic when many cases of BE are classified as IND (60% of dysplastic cases in a study by 100 Alshelleh et al. [25]) and when the interobserver agreement is even poorer than for LGD [26]. 101 There is emerging evidence that the addition of biomarkers to risk stratification models could 102 increase BE diagnostic accuracy compared to current surveillance methods [27]. These 103 biomarkers range from the incorporation of more clinical variables [28, 29] to molecular 104 features such as genomic instability [30–34], gene expression patterns [35, 36], epigenetics 105 [37, 38], and proteomics [39]. In addition to biomarkers, the recent emergence of artificial 106 intelligence (AI) tools opens the prospect of improving the effectiveness of BE diagnosis and 107 surveillance. A recent meta-analysis revealed that deep learning algorithms applied to 108 endoscopy images in the surveillance of BE-related neoplasia are highly accurate (pooled 109 sensitivity and specificity of 90.3% and 84.4%, respectively) in detecting early HGD/EAC [40], 110 despite the absence of data for LGD. However, most diagnostic and prognostic tools 111 (biomarkers, AI), still lack substantial validation in large patient cohorts, refraining from their 112 usage in clinical practice [41]. In addition, the new tools available do not reach yet maximum 113 performance. For example, when predicting the neoplastic progression to HGD/EAC, both TP53 114 staining and Tissue Cypher test demonstrate high specificity (86% and 82%, respectively) but 115 to the detriment of low sensitivity/recall (49% and 55%, respectively) [reviewed by [42]]. 116 While it is not yet clear whether regular surveillance surely leads to earlier detection of

dysplasia and consequently to a decrease in mortality from EAC [43] surveillance is still the only
recommended strategy for BE and EAC management. There is room for new diagnostic and
prognostic tools to support clinicians when diagnosing BE dysplasia and segmenting patients
based on the risk of BE progression to EAC.

121 The current study explores the diagnostic and prognostic value of gene expression patterns 122 from BE tissue samples from public datasets in the context of BE. Envisioning its clinical

applicability, it aims to identify biomarkers that can accurately identify dysplasia within BE lesions (diagnostic application) and biomarkers that can predict the progression to EAC (prognostic application). It is also intended to understand the individual and combined predictive value of each selected biomarker in both contexts through their implementation using machine learning algorithms.

### 129 2. MATERIALS AND METHODS

### 130 2.1. Dataset Search:

131 An exhaustive search for public datasets containing gene expression data related to BE, 132 including normal esophageal epithelium, NDBE, BE with different degrees of dysplasia (LGD 133 HGD) performed following Pubmed and and EAC was in the databases: 134 (https://pubmed.ncbi.nlm.nih.gov/), Omnibus (GEO, Gene Expression 135 https://www.ncbi.nlm.nih.gov/geo/), Sequence Read Archive (SRA, 136 https://www.ncbi.nlm.nih.gov/sra), and European Genome-Phenome Archive (https://ega-137 archive.org/). For the diagnostic application, the aim was to distinguish between NDBE and 138 LGD BE. For the prognostic application, non-progressed BE (nonP-BE) and progressed BE (P-139 BE) data was studied. P-BE was defined as a BE adjacent to EAC. A summary of the methodology 140 used is represented in Figure 1 and described in detail below.

141



143 **Figure 1 – Methodology Summary.** Datasets of interest were downloaded from public databases, such 144 as PubMed, GEO (Gene Expression Omnibus), SRA (Sequence Read Archive), and EGPA (European 145 Genome-Phenome). For the diagnostic application, i.e., the distinction between non-dysplastic (ND) BE 146 and low-grade dysplasia (LGD) BE, RNAseq datasets were used. Low-expression genes were excluded, 147 resulting in a pre-selection of 45 genes. For the prognostic application, i.e., the distinction between 148 non-progressed Barrett's Esophagus (nonP-BE) and progressed-BE (P-BE), microarray datasets were 149 identified, and 25 previously described genes were selected [35]\*\*. A Thresholding Function was 150 applied to each gene to define the best gene expression threshold for group distinction. All analyzed 151 genes were ranked by F1 score, and additional feature selection methods were applied for diagnostic 152 genes\*, determining the top genes for diagnosis and prognostic application. Due to their biological 153 functions, two extra genes – TP53 and CDH1 – were added to both diagnostic and prognostic data sets, 154 summing 18 diagnostic and 15 prognostic genes. Different algorithms – Logistic Regression (LR), Naive 155 Bayes (NB), K-nearest neighbours (KNN), Linear Support Vector Machines (LSVM), and Radial Basis 156 Function Support Vector Machines (RBF SVM) - were trained using different numbers of genes.

Algorithms' performance was assessed through accuracy, recall (sensitivity), precision (positive
 predictive value – PPV), F1 score, Specificity and negative predictive value (NPV). [35]

139

### 160 2.2. <u>Data Pre-Processing:</u>

161 In this study, raw RNA-seq data from projects GSE193946, GSE58963, and E-MTAB-4054 were 162 obtained from the Sequence Read Archive (SRA) and the European Genome-Phenome Archive 163 (EGA). We processed the data using a Docker environment equipped with Kallisto version 164 0.46.1 (docker image: ilnetosci/kallisto:v0.46.1), which facilitated the pseudo-alignment of the 165 reads against the Homo sapiens.GRCh38.cdna.all.release-107 reference transcriptome from Ensembl. Post-alignment, the transcript abundance estimates generated by Kallisto were 166 167 imported into the R programming environment using the tximport package. This allowed 168 transcript-level data to be transformed into gene-level counts, which were subsequently 169 analyzed for differential expression. The combined data was filtered for low-expressed genes 170 using the filterByExpr function in EdgeR [44], resulting in a dataset of 20,608 genes for 171 downstream analysis. Samples were then normalized using the TMM (Trimmed Mean of M-172 values) normalization method and differential expression analysis was performed using EdgeR 173 [31]. For downstream analysis, including feature selection and classifier training, log-174 transformed CPM normalized values were used, which were subsequently corrected for batch 175 effects using the ComBat function from the sva package [45].

In this study, microarray data was sourced from the Gene Expression Omnibus (GEO) database using the GEOquery package available in the R software. The data included accessions GSE1420, GSE363223, GSE13083, GSE37200, GSE34619, GSE26886, GSE39491, GSE100843, and an additional dataset from Watts et al. (2007) [46]. Data was loaded and normalized using both the affy and oligo packages in R, depending on the array platform. The CEL files were read and processed using the frma function for robust multi-array average (RMA) normalization.

182 Probe-level data was annotated and collapsed to gene-level data using Bioconductor 183 annotation packages hugene10sttranscriptcluster.db, hgu133a.db, hgu133plus2.db, and 184 hgu133a2.db along with the WGCNA package. Finally, the resulting gene expression data was 185 merged into a single dataset for downstream analysis, with additional annotations indicating 186 BE progression status [42][43]. For prognostic application, 25 genes selected in previous work 187 to distinguish nonP-BE from P-BE [35], were used in this study – ACTN1, C1S, CCN1 (alias 188 CYR61), CDH1, CEBPB, CEBPD, COL4A1, CTSB, DKK3, DUSP1, IER3, JUN, LAMC1, PLPP3, RBPMS, 189 SNAI1, SNAI2, SPARC, TNS1, TRMT112, TP53, TWIST1, VWF, WWTR1 (alias TAZ) and ZEB1. Box 190 plots representing normalized expression values were generated using the ggplot2 (v3.4.0) and 191 ggsignif (v0.6.4) R packages. Statistical analysis was performed using one-way ANOVA, followed 192 by a *post hoc* Tukey's 'Honest Significant Difference' test, both from the R stats package 193 (v4.1.1). When ANOVA assumptions were not met, a Kruskal-Wallis Rank Sum Test (R stats 194 package v4.1.1) was performed, followed by a *post hoc* Dunn's Kruskal-Wallis Multiple 195 Comparisons test (FSA R package v0.9.3). The significance threshold was set at p-value < 0.05.

196

### 197 2.3.

### Threshold selection and determination of individual predictive power:

198 For the distinction between NDBE and LGD (diagnostic) or nonP-BE and P-BE (prognostic) a 199 Thresholding function was applied to the expression levels of each selected gene to determine 200 an expression threshold. Performance metrics such as accuracy, recall (or sensitivity), precision 201 (or positive predictive value – PPV), specificity, negative predictive value (NPV), and false 202 positive rate (FPR) were calculated for each threshold, considering the known class of the 203 samples. For the diagnostic application, other feature selection methods (Lasso, Mutual 204 Information (MI) criteria, Recursive Feature Elimination (RFE), SelectKBest) were also applied 205 to narrow down the most informative features that appeared at least twice in one of the

206 methods. The threshold that yielded the highest F1-score was selected. Based on this metric, 207 genes were ranked and the top 16 (diagnostic) and top 13 (prognostic) were considered for 208 downstream analysis. Two additional genes – *TP53* and *CDH1* – were also included in the 209 downstream analysis of both prognostic and diagnostic gene sets.

- 210
- 211

### 2.4. <u>Algorithmic analysis and evaluation of performance metrics:</u>

212 Gene expression values were used for algorithm training. Several classes of classifiers, with shown applicability to microarray and RNAseq data [47-49], such as Logistic Regression (LR), 213 214 Naive Bayes (NB), K-nearest neighbours (KNN), and Support Vector Machines (SVM) (with 215 Linear and Radial Basis Function kernels), were implemented with default hyperparameters in 216 Python programming language (v3.10.0), using the scikit-learn package (v1.0.1). A leave-one-217 out cross-validation procedure was used to evaluate the diagnostic or prognostic value of all 218 possible combinations of genes (from n=2 up to all selected diagnostic or prognostic genes). 219 This involved leaving out one sample at a time for validation while using the remaining samples 220 to create a balanced training set. The Synthetic Minority Oversampling Technique (SMOTE) 221 was employed from the imbalanced-learn (v0.8.1) package. For LR, KNN, and SVM, features 222 were standardized (scaled and centered) using scikit- learn's standard scaler module by 223 subtracting the mean and scaling to the unit variance. Performance metrics such as accuracy, 224 precision (PPV), recall (sensitivity), NPV, and precision and specificity were calculated and 225 recorded for each full iteration of the validation strategy. The top-performing algorithms were 226 chosen by maximizing performance metrics (accuracy, specificity, precision, recall, NPV, and 227 F1-score, Table 2). The most frequent models, with the highest F1-score, were chosen to 228 further select the best classifiers for both diagnostic and prognostic applications. The most 229 frequently occurring genes (frequency  $\geq$  50 %) within the selected classifiers were chosen as

- 230 features. Subsequently, the performance metrics were calculated using a decremental number
- 231 of features, and the median value and standard deviation of each group of decremental
- 232 subsets of genes were computed.
- 233
- 234 2.5. *In-vivo* gene expression analysis:
- 235 2.5.1. <u>RNA extraction</u>:
- 236 Cell pellets from the cell lines metaplasia (BAR-T and BAR-T10 from R. Souza, Baylor
- 237 University Medical Center, Dallas, TX; Jaiswal et al., 2007; X. Zhang et al., 2010), dysplasia (CP-
- B, CP-C and CP-D from P. Rabinovitch, University of Washington, Seattle, WA; Palanca-
- 239 Wessels et al., 2003), and EAC (OE33, KYAE-1- from W. Dinjens, Erasmus Medical Center
- 240 Cancer Institute, Rotterdam, Netherlands, and ESO26 Boonstra et al., 2010) were used to
- extract RNA using the RNeasy Mini Kit (#74104, Qiagen, Hilden, Germany), following the
- 242 manufacturer's instructions.
- 243 For formalin-fixed paraffin-embedded (FFPE) tissue samples, RNA was isolated from 2
- 244 consecutive sections per sample, each approximately 20 mm2 and 5 µm. Tissue samples
- were deparaffinized using the deparaffinization solution (#19093, Qiagen, Hilden, Germany)
- prior to RNA extraction with the RNeasy FFPE Kit (#73504, Qiagen, Hilden, Germany),
- 247 according to the manufacturer's instructions (with one modification: proteinase K incubation
- 248 was performed overnight).
- All procedures involving human tissue samples were approved by the National Ethics
- 250 Committee for Clinical Research Comissão de Ética para a Investigação Clínica (CEIC), under
- approval number 2022\_EO\_24.
- 252

# 253 2.5.2. <u>Reverse Transcription - quantitative real-time Polymerase Chain Reaction (RT-</u> 254 qPCR):

255 For 1-Step RT-qPCR, reactions were performed in triplicate, using the TaqPath 1-step RT-qPCR 256 Master Mix (#A15300, Thermo Fisher Scientific) with a final reaction volume of 10 µL. Each 257 reaction containing 1  $\mu$ L of template, 0.25  $\mu$ M of probe and 0.5  $\mu$ M of each primer. Data 258 acquisition and analysis were conducted using the QuantStudio Design & Analysis Software 259 v1.5.1 software, using the cycling program: UNG incubation at 25°C - 2 minutes, Reverse 260 Transcription at 50°C - 15 minutes, followed by Polymerase activation at 95°C - 2 minutes and 261 40 cycles of Amplification at 95°C - 3 s and 58°C - 30 s. To normalize gene expression levels, 262 the geometric mean of the reference genes (PGK1, ELF1, and RPL13A) was subtracted from 263 cycle threshold (Cq) of the target genes.

#### 265 3. RESULTS:

#### 266 3.1. Diagnosis and prognosis dataset selection

267 For the development of the diagnostic application, 13 RNAseq-based datasets were identified,

- 268 of which only 3 had publicly available clinical data – GSE58963 [50], E-MTAB-4054 [51],
- 269 GSE193946 [52] – and were therefore included in the present study. The BE data contained in
- 270 each dataset is represented in **Table 1**. In total, data from 61 samples – comprising 21 NDBE,
- 271 40 LGD BE and 27 HGD – were included in the study.
- 272

#### 273 Table 1 – Characterization of datasets for the diagnostic and prognostic applications

Dataset		Diagnostic		Prognostic (Microarray)				
	NDBE		НСР		P-RF*			
GSE1420 [53]	-	-	-		16			
Watts 2007 [46]	-	-	-	18	0			
GSE36223 [54]	-	-	-	23	0			
GSE13083 [55]	-	-	-	7	0			
GSE37200 [56]	-	-	-	0	46			
GSE34619 [57]	-	-	-	10	0			
GSE26886 [58]	-	-	-	20	0			
GSE39491 [59]	-	-	-	40	0			
GSE100843 [60]	-	-	-	17	3			
GSE58963 [50]	7	7	7	-	-			
E_MTAB_4054 [51]	14	8	-	-	-			
GSE193946 [52]	0	25	20	-	-			
TOTAL N. samples	21	40	27	135	65			

274 nonP-BE – non progressed Barrett's esophagus, P-BE – progressed Barrett's esophagus, NDBE – non-

275 dysplastic Barrett's esophagus,

276 LGD – low-grade dysplasia, HGD – high-grade dysplasia.

- 277 \*P-BE was defined when a BE was adjacent to EAC
- 278

For the prognostic application, 16 microarray datasets were identified, but only those 279 280 generated on an Affymetrix platform were included in the downstream analysis to facilitate 281 data merging. A total of 9 microarray datasets were analyzed, including three previously 282 analyzed by Cardoso, et al [35], - GSE1420 [53], Watts 2007 [46], and GSE13083 [55] and six 283 new ones, namely GSE36223 [54], GSE37200 [56], GSE34619 [57], GSE26886 [58], GSE39491 [59], and GSE100843 [60]. In total, data from 200 samples – representing 135 nonP-BE and 65
P-BE – were included in the study as shown in Table 1.

286

### 287 3.2. Identification of differentially expressed genes in a diagnostic and

288 prognostic setting

In this study, we aimed to identify diagnostic biomarkers that can distinguish between ND-BE and LGD-BE. For this purpose, we utilized three RNAseq datasets (as listed in **Table 1**). Lowexpression genes were excluded from each dataset, resulting in the inclusion of 20608 genes in our analysis. After normalization, we conducted differential expression analysis between LGDBE and NDBE (Figure S1A), and HGDBE and NDBE (Figure S1B) using EdgeR's quasilikelihood approach. This approach accounted for disease staging and batch effects from the three different datasets as factors in the model (Supplementary Table 1, Figure S1C).

296 Following the differential expression analysis, we identified 30 biomarkers through a 297 systematic selection process. First, we selected differentially expressed genes (DEGs) with an 298 absolute log fold change (logFC) of  $\geq$  1 between LGDBE and NDBE, with a false discovery rate 299 (FDR) of < 0.05. From these DEGs, we filtered for genes that showed the same direction of 300 expression change in the HGDBE vs. NDBE comparison (FDR < 0.05), resulting in 14 genes 301 (Figure S1A). Second, we identified DEGs in the HGDBE vs. NDBE comparison with an absolute 302 logFC of  $\geq$  2 (FDR < 0.05). Among these genes, we selected those that also exhibited the same 303 direction of expression change in the LGDBE vs. NDBE comparison (considering p-value < 0.05 304 for significance), resulting in 16 genes (Figure S1B). This two-step filtering strategy ensured 305 that the selected biomarkers not only had significant differential expression but also consistent 306 expression patterns across different stages of disease progression. Given the strong batch 307 effect observed (see Figure S1), there was a risk of losing biologically relevant genes in the

308 LGDBE vs. NDBE comparison due to this variation. To mitigate this problem, we also performed 309 separate analyses of the EMTAB 4054 (Supplementary Table 2) and GSE58963 310 (Supplementary Table 3) datasets. We employed the glmRobust pipeline to independently 311 identify differentially expressed genes between the LGDBE and NDBE groups within each 312 dataset. From these separate analyses, we identified an additional 13 genes with an absolute 313 logFC greater than 1 and an FDR < 0.05. These genes were consistently found in both datasets 314 and exhibited the same direction of expression change (Figure S2). Moreover, these genes 315 showed consistent directional changes in the previous HGDBE vs. NDBE comparison. Thus, they 316 were also included in the biomarker list (Supplementary Table 4). Given their established role 317 in the biology of BE and EAC, we also included two additional genes – TP53 and CDH1 –in the 318 downstream analysis, resulting in a total of 45 candidate genes for distinguishing between 319 NDBE and LGD.

For the prognostic set of biomarkers, we re-analyzed 25 genes that we had previously identified to have prognostic value [35], namely *ACTN1*, *C1S*, *CCN1* (alias *CYR61*), *CDH1*, *CEBPB*, *CEBPD*, *COL4A1*, *CTSB*, *DKK3*, *DUSP1*, *IER3*, *JUN*, *LAMC1*, *PLPP3*, *RBPMS*, *SNAI1*, *SNAI2*, *SPARC*, *TNS1*, *TP53*, *TRMT112*, *TWIST1*, *VWF*, *WWTR1* (alias *TAZ*) and *ZEB1*. For validation purposes, we added six independent datasets to the three datasets we originally analyzed. We observed significant differential gene expression (adj. *p-value* < 0.05) between P-BE and nonP-BE categories for most of the genes of interest, except for *CDH1*, *DKK3*, *SNAI2*, *and WWTR1*.

- 327
- 328 3.3. Application of a Thresholding function for the selecting genes with the
   329 highest predictive value

To each selected gene, we applied a Thresholding function, to determine a gene expressionthreshold for distinguishing different levels of gene expression between groups of samples

332 with distinct diagnosis (NDBE vs. LGD-BE) or with distinct prognosis (nonP-BE vs. P-BE). We 333 defined the best individual threshold of gene expression for each selected gene, 45 for 334 diagnosis and 25 for prognosis, reflecting the individual predictive value of each gene. Genes 335 were then ranked by the harmonic mean of recall and precision (F1-score) to ensure accurate 336 selection. This procedure identified the top 15 genes for predicting the malignant progression 337 of BE lesions with F1-score above 0.67 (Supplementary Table 5). From the top 45 diagnostic 338 genes, including CDH1 and TP53, genes with higher expression values (log2CPM above 1) were 339 filtered. To further refine a list of candidates, we used several feature selection methods: Lasso, 340 Mutual Information (MI) criteria, Recursive Feature Elimination (RFE), and SelectKBest. 341 Additionally, feature correlation analysis was conducted to identify and eliminate highly 342 correlated features (Pearson's correlation coefficient > 0.9). Hence, for diagnostic purposes, 343 we further narrowed down the selection to genes that were chosen at least twice in one of the 344 feature selection methods and F1-score above 0.7, which identified the top 16 genes for 345 diagnosing dysplasia in the context of BE (Supplementary Table 6).

Building on our identification of the top diagnostic and top prognostic genes using the Thresholding function and various feature selection methods, the ROC curve results (Figure 2) further validate their predictive power using a logistic regression classifier. In both diagnostic (Figure 2A) and prognostic (Figure 2B) contexts, most of the genes have AUC (Area Under the Curve) values above 0.50 (random chance line), with some reaching individual values of 0.90, demonstrating a substantial predictive value of the selected genes in both diagnostic and prognostic applications.

All rights reserved. No reuse allowed without permission.



# **B** Prognostic (progression)



Figure 2 – Gene-Specific ROC Curves for Diagnostic and Prognostic Predictions. Receiver Operating
 Characteristic (ROC) curves for individual genes depicting their predictive value in two contexts: (A)
 Diagnostic (dysplasia) and (B) Prognostic (progression) using a logistic regression classifier. The Area
 Under the Curve (AUC) values for each gene are indicated in the legends. Notably, the predictive values
 of TP53 and CDH1 genes are also included, although they were manually added to the sets.

### 361 3.4.SVM algorithms were the best for both diagnostic and prognostic applications

- 362 The diagnostic and prognostic gene groups were utilized to train the most effective diagnostic and
- 363 prognostic algorithms. Various classifiers LR, NB, KNN, LSVM, and RBF SVM were examined using
- increasing combinations of genes, ranging from n = 2 up to the total number, for diagnostic and
- 365 prognostic applications.
- 366 The algorithms were ranked based on their performance metrics for each application (see **Table 2**).
- 367 However, no algorithms optimized all performance metrics for both applications. Nevertheless, the
- 368 LSVM algorithms emerged as the best for diagnostic purposes, maximizing the F1-score and accuracy
- 369 (refer to Figure 3A and Table 2).
- For the prognostic application, a similar trend was observed, where the RBF SVM type performed best
- according to the F1-score and accuracy metrics (refer to **Figure 3B** and **Table 2**).
- 372

Application	Rank by	N. algorithms	Type of algorithm	Recall	Precision	F1 - score	Specificity	NPV	Accuracy
	Recall	4871	KNN (n=196) LSVM (n=2426) LR (n=124 RBF SVM (n=2125)	0.99	0.78- 0.98	0.88- 0.99	0.48-0.95	1.00	0.82- 0.98
Diagnostic	Precision	3050	KNN (n=2290) LSVM (n=472) LR (n=259) NB (n=21) RBF SVM (n=8)	0.65- 1.00	0.97	0.79- 0.99	0.95-1.00	0.60- 1.00	0.77- 0.98
	F1-score	1881	KNN (n=288) LSVM (n=1115) LR (n=444) RBF SVM (n=34)	0.92- 1.00	0.93- 1.00	0.96	0.86-1.00	0.88- 1.00	0.95- 0.98

373 Table 2 – Best algorithm performance by metric maximization

Application	Rank by	N. algorithms	Type of algorithm	Recall	Precision	F1 - score	Specificity	NPV	Accuracy
	Specificity	231	KNN (n=223) LSVM (n=8)	0.65- 0.95	1.00	0.79- 0.97	0.99	0.60- 0.91	0.77- 0.97
	NPV	4871	KNN (n=196) LSVM (n=2426) LR (n=124) RBF SVM (n=2125)	1.00	0.78- 0.98	0.88- 0.99	0.48-0.95	0.99	0.82- 0.98
	Accuracy	212	KNN (n=38) LSVM (n=157) LR (n=16) RBF SVM (n=1)	0.95- 1.00	0.95- 1.00	0.97- 0.99	0.90-1.00	0.91- 1.00	0.96
Prognostic	Recall	13	LR (n=7), LSVM (n=5), RBF SVM (n=1)	0.97	0.69- 0.70	0.81	0.79-0.80	0.98	0.85- 0.86
	Precision	582	RBF SVM (n=449) KNN (n=24) LSVM (n=17) NB (n=92) LR (n=348)	0.88- 0.95	0.99	0.93- 0.98	1.00	0.94- 0.98	0.96- 0.98
	F1-score	12971	RBF SVM (n=5794) KNN (n=2465) LSVM (n=2230) NB (n=2134) LR (n=348)	0.92- 0.95	0.97- 1.00	0.96	0.99-1.00	0.96- 0.98	0.98
	Specificity	8430	KNN (n=586) LSVM (n=569) LR (n=38)	0.83- 0.95	0.98- 1.00	0.9- 0.98	0.99	0.92- 0.98	0.94- 0.98

All rights reserved. No reuse allowed without permission.

Application	Rank by	N. algorithms	Type of algorithm	Recall	Precision	F1 - score	Specificity	NPV	Accuracy
			NB						
			(n=1953)						
			RBF SVM						
			(n=5284)						
			LR (n=7),						
			LSVM		0.60				0.95
	NPV	13	(n=5) <i>,</i>	0.97	0.69-	0.81	0.79-0.80	0.98	0.65-
			RBF						0.00
			SVM(n=1)						
			KNN						
			(n=264)						
			LSVM						
			(n=370)	0.04		0.07			
	Accuracy	2404	LR (n=28)	0.94-	0.98-1	0.97-	0.99-1	0.98	0.98
			NB	0.95		0.96			
			(n=415)						
			RBF SVM						
			(n=1327)						

374 LR – logistic regression, LSVM – linear support vector machine, RBF SVM – radial basis function support vector

375 machine, KNN – K-nearest neighbors, NB – Naïve Bayes. Selected algorithms are highlighted in grey.

376



<sup>377</sup> 

378 Figure 3 - Precision and Recall for the selected classifier type with increasing combinations of genes of 379 interest to predict BE dysplasia (diagnostic) and BE malignant progression (prognostic). This illustrates 380 the performance of the chosen classifier types in the predicting dysplasia (A) and progression (B) when 381 different numbers of genes of interest are combined (colored dots). The individual predictive value for the 382 best threshold of each previously selected gene is also represented (black dots) for diagnostic (see Figure 383 3A) and prognostic (see Figure 3B). Colors represent different numbers of combined genes. LSVM – Linear 384 Support Vector Machine (A), and RBF SVM – Radial Basis Function Support Vector Machine (B). Red dots 385 represent manually added CDH1 and TP53 genes.

387 The study found that among the selected types of algorithms, those with an F1-score above 388 0.96 included 1115 LSVM for diagnostic and 5794 RBF SVM for prognostic. The analysis 389 identified the most frequent genes (over 50%) across the best-performing algorithm class 390 (Supplementary Table 7 and Supplementary Table 8). Ultimately, ten genes were selected for 391 identifying LGD BE using a LSVM algorithm: IGHV3-43, SLC38A4, PLLP, CELA3A, IGHV4-31, 392 TMPRSS5, TP53, NR4A1, ATF3, IFI27. For identifying P-BE, ten genes were selected using an 393 RBF SVM algorithm: SNAI1, C1S, DUSP1, CEBPB, COL4A1, ZEB1, CEBPD, CCN1, LAMC1 and 394 TWIST1.

395

396 The performance of each selected algorithm (LSVM for diagnosis and RBF SVM for prognosis) 397 was evaluated using the most frequent genes (10 for diagnosis and 10 for prognosis) as 398 features. To test different random states while avoiding algorithm bias, 100 runs were 399 performed for each algorithm with the same features. Table 3 presents the mean values and 400 respective standard deviations (SD) for each performance metric. All performance metrics 401 were above 0.90, except for specificity for the LSVM diagnostic algorithm. The low standard 402 deviations (below 0.05) indicated an increase in the predictive value of each algorithm when 403 the selected genes were combined.

404

405

406

407

408

409

All rights reserved. No reuse allowed without permission.

### 411 Table 3 – Performance of the selected algorithms with the selected genes as features after 100 runs

A. Diagnostic			_	B. Prognostic	:	
	Mean	Standard deviation			Mean	Standard deviation
Accuracy	0,946	0,014		Accuracy	0,977	0,003
Precision	0,932	0,012		Precision	0,977	0,008
Recall	0,991	0,017		Recall	0,952	0,005
F1 score	0,960	0,010		F1 score	0,965	0,004
ТР	39,630	0,677		ТР	61,900	0,302
FP	2,900	0,541		FP	1,430	0,498
TN	18,100	0,541		TN	133,570	0,498
FN	0,370	0,677		FN	3,100	0,302
NPV	0,981	0,033		NPV	0,977	0,002
Specificity	0,862	0,026		Specificity	0,989	0,004
FPR	0,138	0,026		FPR	0,011	0,004

412 TP- True Positive, FP- False Positive, TN- True Negative, FN- False Negative, NPV- Negative Predictive Value, FPR-

413 False Positive Rate.

414

Finally, the performance of the two algorithms was evaluated by gradually decreasing the number of selected genes (**Figure 4**). The diagnostic algorithm showed a decrease in performance after the removal of just one gene (**Figure 4A**). In contrast, the prognostic algorithm showed noticeable changes only after the removal of four genes (**Figure 4B**).





the training. Mean of each performance metric (solid lines) and its respective standard deviation
(ribbons) for the diagnostic algorithm, Linear Support Vector Machine (LSVM) (A) and for the prognostic
algorithm, Radial Basis Function Support Vector Machine (RBF SVM) algorithm (B) NPV – negative
predictive value.

- 426
- 427
- 428 429

### 430 **3.5**. *In-vivo* validation of key diagnostic and prognostic biomarkers

We conducted a validation study of the panel of biomarkers to distinguish between different stages of BE progression. Specifically, we performed RT-qPCR analysis to compare the expression levels of these biomarkers in differente cell lines: metaplasia (BAR-T and BAR-T10), dysplasia (CP-B, CP-C and CP-D), and EAC (OE33, KYAE-1 and ESO26). Each biomarker was tested with three technical replicates in each cell line.

436 For dysplasia diagnosis, we analyzed the expression of biomarkers in both metaplasia and 437 dysplasia cell lines (Figure S6). In evaluating EAC prognosis, we compared the expression levels 438 between metaplasia and EAC cell lines (Figure S7). Normalized expression values against 439 reference genes (PGK1, ELF1 and RPL13A) highlighted significant differences in key markers. 440 For instance, biomarkers such as *IFI27* and *ATF3* differentiated metaplasia from dysplasia with 441 statistically significant p-values (p = 0.009 and p = 0.003, respectively), revealing their potential 442 utility in dysplasia diagnosis. Similarly, CEBPB, SNAI1 and CCN1 (alias CYR61) genes showed 443 significant expression changes between metaplasia and EAC (p-values of 0,031, 0.022 and 444 0.038, respectively). This supports their relevance for EAC prediction. The observed differential 445 expression patterns suggest that these biomarkers serve as valuable molecular tools for early 446 detection of dysplasia and the risk of progression to EAC, facilitating timely clinical intervention. 447 Interestingly, some of the top-performing genes, namely IGHV3-43, IGHV4-31, IGHV3-53, and 448 PGC, showed no detectable expression in cell lines. Since these genes ranked high according

to the diagnostic algorithm, we hypothesized that their expression originates from immune
cells, typically absent in cell lines. To investigate this further, we specifically tested these genes
in tissue samples from BE patients with and without dysplasia. Contrary to cell lines, the
expression of these genes was detectable in patient samples, supporting the notion that
immune cells- may play a critical role in BE progression (Figure S6).

### 456 **4.** DISCUSSION:

457 BE is the only known precursor to EAC, a malignancy with rising incidence and poor prognosis. 458 This underscores the need for more effective management methods, including assertive early 459 diagnosis of dysplasia and prognostic prediction within BE surveillance programs. While tools 460 incorporating biomarkers are continuously emerging, few have reached clinical validation and 461 implementation. Even fewer combine biomarkers with AI and those under clinical validation or 462 use, do not provide simultaneous detection of dysplasia and prognostic assessment. Moreover, 463 none can simultaneously achieve high sensitivity (recall) and high specificity.

In this study, we developed two algorithms to assist with the diagnosis of dysplasia, the prognosis of BE, and ultimately the management of EAC. The genes of interest for dysplasia detection (diagnostic algorithm) were newly identified from the raw data of three different RNAseq datasets. Conversely, the algorithm developed for prognosis was based on a gene set identified in a previous study [35]. For both applications, genes were ranked based on their F1 score, sensitivity (*aka* recall or true positive rate) and precision (*aka* positive predictive values) in predicting conditions such as LGD BE and P-BE.

471 In high-risk disease detection cases such as dysplasia, recall is a more important evaluation 472 metric than precision because it can correctly identify all relevant positive cases (*i.e.*, samples 473 containing dysplasia or at high risk of progressing to EAC). However, precision, which is the 474 fraction of positive cases among all cases classified as positives by the model, is also crucial 475 because it emphasizes the correctness of positive predictions made by the model (i.e., 476 measures how many cases are incorrectly classified as positive). In a situation where false 477 positives have significant implications, such as subjecting BE patients without dysplasia or with 478 a low risk of progression to unnecessary treatments or screening intervention, precision 479 matters. Since both high precision and high recall were desirable for the present study, the

480 ranking was based on the F1 score, which combines precision and recall using their harmonic 481 mean. Maximizing the F1 score implies maximizing both precision and recall simultaneously. 482 Performance metrics for each gene at its best threshold were high (see Supplementary Tables 483 5 and 6). However, specificity and NPV were higher for the prognostic genes, showing their 484 great potential to exclude patients who are not at risk for malignant progression. 485 To better explore the potential predictive value of the selected biomarkers, we trained 486 machine learning algorithms testing all possible combinations of biomarkers in each gene set. 487 The average metrics of the newly trained algorithms with combinations of biomarkers showed 488 increased predictive power (Table 2) compared to the predictive power of individual genes 489 (Supplementary Tables 5 and 6), which is expected in the context of complex gene interactions. 490 Finally, envisioning the clinical applicability of both algorithms, we evaluated the minimal 491 number of biomarkers necessary to maintain high-performance metrics (LSVM for diagnosis 492 and RBF SVM for prognosis) in each gene set. Both algorithms were tested with a decreasing 493 number of genes, and as depicted in Figure 4, a reduction in performance metrics was 494 observed when removing one gene from the diagnostic set and four genes from the 495 prognostic's gene set.

For diagnostic application, ten genes- *IGHV3-43*, *SLC38A4*, *PLLP*, *CELA3A*, *IGHV4-31*, *TMPRSS5*, *TP53*, *NR4A1*, *ATF3*, *IFI27*- were identified as the top candidates for dysplasia detection, particularly for distinguishing between NDBE and LGD BE. These genes are associated with different aspects of cancer biology, such as metabolism, cell invasion, and oncogenic processes, suggesting their potential as biomarkers in the context of BE dysplasia [61–64]. Moreover, transcription factors such as *NR4A1* and *ATF3*, have been previously associated with BE with LGD [65].

503 For the prognostic application, an RBF SVM algorithm was selected, which uses the expression 504 pattern of ten genes (SNAI1, C1S, DUSP1, CEBPB, COL4A1, ZEB1, CEBPD, CCN1, LAMC1 and 505 TWIST1). Four of these genes – SNAI1, COL4A1, ZEB1, and TWIST – have been associated with 506 epithelial-to-mesenchymal transition [66]. COL4A1, ZEB1, and TWIST1 have also been 507 described as potential screening biomarkers of BE malignant progression. COL4A1 is 508 upregulated in EAC versus BE [67–69] and is associated with poor EAC prognosis [68], and it 509 predicts the response to immune checkpoint inhibitors in EAC [67]. Increased expression of 510 ZEB1 has been associated with the repression of CDH1 [70], which is associated with BE 511 progression to EAC [71–75]. TWIST1 up-regulation was observed in at-risk BE samples years 512 before the emergence of any microscopic signs of malignancy (dysplasia/EAC) [35].

513 The genes TP53 and CDH1 were included in both gene sets to train the classifiers. TP53 is 514 known for its role in BE malignant progression [76, 77], improved prediction of BE neoplastic 515 progression [78], increased risk of dysplasia when abnormally expressed, and improved intra-516 observer agreement in dysplastic diagnosis [79]. CDH1 has severely reduced or disorganized 517 expression during BE dysplastic progression [reviewed by [80] and an almost undetectable 518 expression in poorly differentiated EAC [71–75]. While TP53 alone is insufficient for diagnostic 519 and for prognostic applications, it has been shown to have predictive value in combination with 520 other biomarkers in the diagnostic setting. These findings confirm the previously studied role 521 of TP53 in the pathogenesis of BE dysplasia [81, 82]. Because TP53 mutations are often 522 associated with a higher risk of progression in BE patients [83], further validation of this 523 biomarker at the molecular level, including its mutational status and RNA expression levels, is 524 warranted.

All metrics of both algorithms are higher when compared to currently available tools for risk
stratification, such as *TP53* immunohistochemistry (0.49 recall/sensitivity, 0.86 specificity [81])

527 and TissueCypher (0.55 recall/sensitivity, 0.82 specificity for high-intermediate risk class 528 55%/82%) [63]. Tools for dysplasia detection, such as Wats3D and Cytosponge-TFF3. are still 529 under prospective evaluation. Wats3D provides an incremental yield of 7% for any dysplasia 530 subtype but is negative for dysplasia in 62.5% of cases where an endoscopic biopsy 531 confirmation to compare with the gold standard revealed dysplasia [86]. The Cytosponge-TFF3 532 test when combined with a multidimensional biomarker panel and fitted into a regression 533 model was shown to be able to predict patients with dysplasia with good accuracy but further 534 validation is still needed [87]. Interestingly, in our top 45 genes for diagnostic application 535 (Supplementary Table 4), we have identified another trefoil factor, the TFF2, which is BE 536 related gene.

537 A preliminary in vivo validation of the selected diagnostic and prognostic biomarkers was 538 conducted by examining their expression in metaplasia, dysplasia and EAC-derived cell lines. 539 This validation confirmed their differential expression, highlighting their potential in 540 distinguishing BE progression stages. Exceptionally, IGHV3-43, IGHV4-31, IGHV3-53, and PGC 541 top-ranked genes were validated in FFPE samples from patients diagnosed with BE with and 542 without dysplasia due to their lack of expression in the cell lines. The absence of immune cells 543 in cell line cultures, which focus on epithelial cells, likely contributes to these findings. While 544 we cannot exclude that the used cell lines may exhibit genetic differences from the original 545 tissue, which potentially influences their molecular profiles [88], further clinical validation with 546 a selected cohort of patient samples is warranted and is currently underway.

No molecular tools are currently implemented in clinical practice for identifying LGD/HGD BE. Dysplasia is a major biomarker in BE risk stratification, but it is often focal, making accurate characterization of collected BE biopsy challenging [89], and leading to many cases of BE classified as INDBE. INDBE is a management limbo for dysplasia, posing problems for clinicians.

Most clinical tools developed for BE focus on risk stratification (prognosis) [28, 37–39, 84, 85, 90] and have a high specificity (identify and correctly exclude BE patients not at risk of progression). Simultaneously, these tools have a lower recall/sensitivity indicating their performance drops in detecting BE patients at true risk of progression.
New tests that aim for high recall and sensitivity are vital to avoid missing unacceptable true positive cases of LGD or HGD, as well as patients at risk of progression. However, these tests

557 must also maintain high precision and high sensitivity to avoid incorrectly including patients

not having dysplasia or having a low risk of progression. This balance can improve surveillance

of high-risk patients while reducing unnecessary procedures for low-risk patients, ultimately lowering patient management costs. Our approach, which combines machine learning algorithms with gene expression signatures, represents a promising breakthrough in healthcare. It has the potential to significantly enhance both the diagnosis and prognosis of

563 dysplasia by delivering high recall and precision into clinical practice.

### 565 5. CONCLUSIONS:

This study not only identified biomarkers and developed algorithms to detect LGD in BE biopsies and predict the progression of BE to EAC, but also paved the way for creating new *invitro* laboratory tests for the diagnosis and prognosis of BE. Both algorithms were developed using datasets from public databases analyzing tissue samples obtained during routine endoscopy.

571 For the prediction of BE malignant progression, an LSVM algorithm featuring the identification 572 of LGD was trained while an RBF SVM algorithm was trained for the prediction of BE malignant 573 progression. Both algorithms reached high-performance metrics. To our knowledge, no 574 existing tools can simultaneously detect dysplasia and assess the risk of progression with such 575 high precision and recall.

Validation of the biomarkers and algorithms presented in this study in an independent test and validation patient cohort is currently under consideration. Additionally, while no other known risk factors (epidemiologic, clinical, histologic) have been combined with the presented biomarkers, incorporating patient demographic and clinical information could further enhance the predictive value of the gene expression algorithms. Future algorithm developments will address this issue, demonstrating how such combinations can significantly boost their predictive power.

583

- 584
- 585
- 586

587

- 589 FUNDING INFORMATION: This work was supported by Ophiomics Precision Medicine own
   590 funding.
- 591
- 592 Formal AUTHOR CONTRIBUTIONS: Migla **Miskinyte**: Conceptualization, analysis, 593 Investigation, Writing – review & editing. Benilde Pondeca: Conducting experiments, Writing 594 - review & editing. José B. Pereira-Leal: Conceptualization, review & editing. Joana Cardoso: 595 Conceptualization, Validation, Investigation, Writing - review & editing. All authors have read 596 and agreed to the published version of the manuscript. 597 598 **CONFLICT OF INTEREST STATEMENT**: The work described here is subject to European Patent 599 Application No. 24172031.7; JPL, JC declare an ownership interest in the company Ophiomics
- 600 Precision Medicine. MM, BP are employees at Ophiomics Precision Medicine.
- 601

Supplementary Material:

Supplementary Table 1 – List of genes used for differential expression analysis across multiple datasets

Supplementary Table 2 – List of differentially expressed genes between NDBE and LGDBE groups, E\_MTAB\_4054 dataset.

Supplementary Table 3 – List of differentially expressed genes between NDBE and LGDBE groups, GSE58963dataset.

Supplementary Table 4 – Top 45 candidate genes.

Ν	Gene	Threshold	F1-score	Recall	Precision	Specificity	NPV	Accuracy	FPR	ΤР	FP	ΤN	FN
1	COL4A1	9.34	0.84	0.75	0.94	0.98	0.89	0.91	0.02	49	3	132	16
2	LAMC1	9.19	0.84	0.88	0.81	0.90	0.94	0.90	0.10	57	13	122	8
3	CEBPB	9.75	0.84	0.80	0.88	0.95	0.91	0.90	0.05	52	7	128	3
4	CCN1	7.68	0.84	0.88	0.80	0.90	0.94	0.89	0.10	57	14	121	8
5	SNAI1	6.61	0.82	0.97	0.71	0.81	0.98	0.86	0.19	63	26	109	2
6	C1S	9.65	0.83	0.83	0.83	0.92	0.92	0.89	0.08	54	11	124	11
7	ZEB1	7.66	0.80	0.91	0.72	0.83	0.95	0.86	0.17	59	23	112	6
8	CEBPD	9.32	0.81	0.83	0.79	0.90	0.92	0.88	0.10	54	14	121	11
9	DUSP1	10.46	0.81	0.82	0.80	0.90	0.91	0.88	0.10	53	13	122	12
10	VWF	8.88	0.77	0.80	0.74	0.87	0.90	0.85	0.13	52	18	117	13
11	TWIST	5.15	0.67	1.00	0.51	0.53	1.00	0.69	0.47	65	63	72	0
12	PLPP3	8.68	0.68	0.94	0.53	0.60	0.95	0.71	0.40	61	54	81	4
13	ACTN1	9.82	0.73	0.74	0.72	0.86	0.87	0.82	0.14	48	19	116	17
14	CDH1	5.70	0.50	1.00	0.33			0.33	1.00	65	135	0	0
15	TP53	7.12	0.62	0.89	0.48	0.53	0.91	0.65	0.47	58	64	71	7

Supplementary Table 5 – Top 15 genes for prognostic: individual genes' predictive metrics.

Ν	Gene	Threshold	F1-score	Recall	Precision	Specificity	NPV	Accuracy	FPR	ΤР	FP	ΤN	FN
1	SLC38A4	-0.21	0.84	0.90	0.78	0.52	0.73	0.77	0.48	36	10	11	4
2	TMPRSS5	-1.14	0.82	0.98	0.71	0.24	0.83	0.72	0.76	39	16	5	1
3	EGR3	0.04	0.82	0.98	0.71	0.24	0.83	0.72	0.76	39	16	5	1
4	TP53	5.05	0.82	0.95	0.72	0.29	0.75	0.72	0.71	38	15	6	2
5	FOSB	1.15	0.82	1.00	0.69	0.14	1.00	0.70	0.86	40	18	3	0
6	NR4A1	3.22	0.81	1.00	0.68	0.10	1.00	0.69	0.90	40	19	2	0
7	SFTPB	-0.10	0.80	0.95	0.69	0.19	0.67	0.69	0.81	38	17	4	2
8	IFI27	3.87	0.79	0.98	0.66	0.05	0.50	0.66	0.95	39	20	1	1
9	PLLP	5.66	0.78	0.95	0.66	0.05	0.33	0.64	0.95	38	20	1	2
10	CELA3A	-3.84	0.78	0.95	0.66	0.05	0.33	0.64	0.95	38	20	1	2
11	ATF3	2.94	0.78	0.95	0.66	0.05	0.33	0.64	0.95	38	20	1	2
12	IGHV3-43	-1.38	0.78	0.95	0.66	0.05	0.33	0.64	0.95	38	20	1	2
13	CDH1	8.61	0.78	0.95	0.66	0.05	0.33	0.64	0.95	38	20	1	2
14	PGC	2.48	0.74	0.88	0.64	0.05	0.17	0.59	0.95	35	20	1	5
15	GKN2	-0.11	0.74	0.88	0.64	0.05	0.17	0.59	0.95	35	20	1	5
16	IGHV4-31	-0.91	0.74	0.88	0.64	0.05	0.17	0.59	0.95	35	20	1	5
17	IGHV3-53	-0.92	0.74	0.88	0.64	0.05	0.17	0.59	0.95	35	20	1	5
18	PNLIPRP1	-2.73	0.72	0.83	0.63	0.10	0.22	0.57	0.90	33	19	2	7

Supplementary Table 6 – Top 18 genes for diagnostic: individual genes' predictive metrics.

(L3VIVI = 1113)					
Gene	Count	Frequency (%)			
IGHV3-43	1115	100.00			
SLC38A4	1097	98.39			
PLLP	1072	96.14			
CELA3A	923	82.78			
IGHV4-31	850	76.23			
TMPRSS5	646	57.94			
TP53	645	57.85			
NR4A1	633	56.77			
ATF3	625	56.05			
IFI27	581	52.11			
PGC	530	47.53			
GKN2	490	43.95			
PNLIPRP1	470	42.15			
SFTPB	460	41.26			
CDH1	379	34.00			
FOSB	369	33.10			
EGR3	355	31.84			
IGV3-53	330	29.60			

Supplementary Table 7 – Gene frequency in the best-performing algorithms for diagnostic (LSVM = 1115)

Supplementary Table 8 – Gene frequency in the best-performing algorithms for prognostic (RBF SVM = 5794)

Gene	Count	Frequency
		(%)
SNAI1	5545	95.70245
DUSP1	3837	66.22368
CEBPB	3791	65.42975
C1S	3672	63.37591
COL4A1	3409	58.83673
LAMC1	3157	54.4874
CEBPD	3121	53.86607
ZEB1	3105	53.58992
TWIST1	2940	50.74215
CCN1	2913	50.27615
TP53	2872	49.56852
ACTN1	2609	45.02934
VWF	2592	44.73593
PLPP3	2336	40.31757
CDH1	1140	19.67553



Figure S1. Identification of 30 biomarkers using all datasets.



Figure S2. Identification of additional 13 biomarkers by analyzing datasets separately.



Figure S3. Heatmap of top 45 genes selected for diagnostics.





Figure S4. Boxplots of gene expression levels of genes potentially associated with low-grade **dysplasia.** Comparison of each gene expression in NDBE and LGDBE samples obtained from a total of 3 datasets. \*\*\* adj. p < 0.001; \*\* adj. p < 0.01; \* adj. p < 0.05; NS adj. p > 0.05.



Figure S5. Boxplots of gene expression levels of genes potentially associated with prognosis. Comparison of each gene expression in nonP-BE and P-BE samples obtained from a total of 9 datasets. \*\*\*\* adj. p < 0.001; \*\* adj. p < 0.01; \* adj. p < 0.05; <sup>NS</sup> adj. p > 0.05.



Figure S6. Boxplots of gene expression levels of diagnostic genes. Comparison of gene expression levels between cell lines representing metaplasia and dysplasia, with expression levels normalized to reference genes (PGK1, ELF1, and RPL13A). \* Genes were additionally tested in FFPE samples from patients diagnosed with BE with and without dysplasia.



Figure S7. Boxplots of gene expression levels of prognostic genes. Comparison of gene expression levels between cell lines representing metaplasia and EAC, with expression levels normalized to reference genes (PGK1, ELF1, and RPL13A).

# **REFERENCES:**

1. Spechler SJ, Souza RF. Barrett's Esophagus. New England Journal of Medicine. 2014;371:836–45.

2. Choi KKH, Sanagapalli S. Barrett's esophagus: Review of natural history and comparative efficacy of endoscopic and surgical therapies. World J Gastrointest Oncol. 2022;14:568–86.

3. Klavan H, Russell MB, Macklin J, Lee E, Aslanian HR, Muniraj T. Barrett's esophagus: A comprehensive review for the internist. Disease-a-Month. 2018;64:471–87.

4. Killcoyne S, Fitzgerald RC. Evolution and progression of Barrett's oesophagus to oesophageal cancer. Nature Reviews Cancer. 2021;21:731–41.

5. Malfertheiner P, Nocon M, Vieth M, Stolte M, Jaspersen D, Koelz HR, et al. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care--the ProGERD study. Aliment Pharmacol Ther. 2012;35:154–64.

6. Fabian T, Leung A. Epidemiology of Barrett's Esophagus and Esophageal Carcinoma. Surgical Clinics of North America. 2021;101:381–9.

7. Cook MB, Shaheen NJ, Anderson LA, Giffen C, Chow WH, Vaughan TL, et al. Cigarette smoking increases risk of Barrett's esophagus: An analysis of the barrett's and esophageal adenocarcinoma consortium. Gastroenterology. 2012;142:744–53.

8. Sinha DN, Abdulkader RS, Gupta PC. Smokeless tobacco-associated cancers: A systematic review and meta-analysis of Indian studies. Int J Cancer. 2016;138:1368–79.

9. Kamat P, Wen S, Morris J, Anandasabapathy S. Exploring the Association Between Elevated Body Mass Index and Barrett's Esophagus: A Systematic Review and Meta-Analysis. Annals of Thoracic Surgery. 2009;87:655–62.

10. Andrici J, Tio M, Cox MR, Eslick GD. Hiatal hernia and the risk of Barrett's esophagus. Journal of Gastroenterology and Hepatology (Australia). 2013;28:415–31.

11. Mittal SK, Abdo J, Adrien MP, Bayu BA, Kline JR, Sullivan MM, et al. Current state of prognostication, therapy and prospective innovations for Barrett's-related esophageal adenocarcinoma: a literature review. J Gastrointest Oncol. 2021;12:1197–214.

12. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.

13. Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, et al. The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020. Gastroenterology. 2022;163:649-658.e2.

14. Then EO, Lopez M, Saleem S, Gayam V, Sunkara T, Culliford A, et al. Esophageal cancer: An updated surveillance epidemiology and end results database analysis. World J Oncol. 2020;11:55–64.

15. Fabian T, Leung A. Epidemiology of Barrett's Esophagus and Esophageal Carcinoma. Surgical Clinics of North America. 2021;101:381–9.

16. Hamade N, Vennelaganti S, Parasa S, Vennalaganti P, Gaddam S, Spaander MCW, et al. Lower Annual Rate of Progression of Short-Segment vs Long-Segment Barrett's Esophagus to Esophageal Adenocarcinoma. Clin Gastroenterol Hepatol. 2019;17:864.

17. Li N, Yang WL, Cai MH, Chen X, Zhao R, Li MT, et al. Burden of gastroesophageal reflux disease in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of disease study 2019. BMC Public Health. 2023;23:1–13.

18. Zhang D, Liu S, Li Z, Wang R. Global, regional and national burden of gastroesophageal reflux disease, 1990–2019: update from the GBD 2019 study. Ann Med. 2022;54:1372–84.

19. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American gastroenterological association technical review on the management of Barrett's esophagus. Gastroenterology. 2011;140.

20. Lee SW, Lien HC, Chang C Sen, Lin MX, Chang CH, Ko CW. Benefits of the Seattle biopsy protocol in the diagnosis of Barrett's esophagus in a Chinese population. World J Clin Cases. 2018;6:753–8.

21. Eluri S, Shaheen NJ. Barrett's Esophagus: Diagnosis and Management. Gastrointest Endosc. 2017;85:889.

22. Visrodia K, Singh S, Krishnamoorthi R, Ahlquist DA, Wang KK, Iyer PG, et al. Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis. Gastroenterology. 2016;150:599-607.e7.

23. Sharma P. Low-grade dysplasia in Barrett's esophagus. Gastroenterology. 2004;127:1233–8.

24. Runge TM, Abrams JA, Shaheen NJ. Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterology Clinics of North America. 2015;44:203–31.

25. Alshelleh M, Inamdar S, McKinley M, Stewart M, Novak JS, Greenberg RE, et al. Incremental yield of dysplasia detection in Barrett's esophagus using volumetric laser endomicroscopy with and without laser marking compared with a standardized random biopsy protocol. Gastrointest Endosc. 2018;88:35–42.

26. Thota PN, Kistangari G, Esnakula AK, Gonzalo DH, Liu X-L. Clinical significance and management of Barrett's esophagus with epithelial changes indefinite for dysplasia. World J Gastrointest Pharmacol Ther. 2016;7:406–11.

27. Shaheen NJ, Falk GW, Iyer PG, Souza RF, Yadlapati RH, Sauer BG, et al. Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. Am J Gastroenterol. 2022;117:559–87.

28. Vaughan TL, Onstad L, Dai JY. Interactive decision support for esophageal adenocarcinoma screening and surveillance. BMC Gastroenterol. 2019;19.

29. Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, et al. NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma. PLoS Med. 2007;4:e67.

30. Trindade AJ, McKinley MJ, Alshelleh M, Levi G, Stewart M, Quinn KJ, et al. Mutational load may predict risk of progression in patients with Barrett's oesophagus and indefinite for dysplasia: A pilot study. BMJ Open Gastroenterol. 2019;6.

31. Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Blount PL, et al. The Combination of Genetic Instability and Clonal Expansion Predicts Progression to Esophageal Adenocarcinoma. 2004.

32. Mokrowiecka A, Wierzchniewska-ŁAwska A, Smolarz B, Romanowicz-Makowska H, Małecka-Panas E. P16 gene mutations in Barrett's esophagus in gastric metaplasia - Intestinal metaplasia - Dysplasia - Adenocarcinoma sequence. Adv Med Sci. 2012;57:71–6.

33. Paulson TG, Maley CC, Li X, Li H, Sanchez CA, Chao DL, et al. Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma. Clinical Cancer Research. 2009;15:3305–14.

34. Merlo LMF, Shah NA, Li X, Blount PL, Vaughan TL, Reid BJ, et al. A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prevention Research. 2010;3:1388–97.

All rights reserved. No reuse allowed without permission.

35. Cardoso J, Mesquita M, Dias Pereira A, Bettencourt-Dias M, Chaves P, Pereira-Leal JB. CYR61 and TAZ upregulation and focal epithelial to mesenchymal transition may be early predictors of barrett's esophagus malignant progression. PLoS One. 2016;11.

36. Selaru FM, Zou T, Xu Y, Shustova V, Yin J, Mori Y, et al. Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarrays. Oncogene. 2022;21:475–8.

37. Moinova HR, Laframboise T, Lutterbaugh JD, Chandar AK, Dumot J, Faulx A, et al. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus. 2018.

38. Jin Z, Cheng Y, Gu W, Zheng Y, Sato F, Mori Y, et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res. 2009;69:4112–5.

39. Abdo J, Wichman CS, Dietz NE, Ciborowski P, Fleegel J, Mittal SK, et al. Discovery of novel and clinically relevant markers in formalin-fixed paraffin-embedded esophageal cancer specimen. Front Oncol. 2018;8 MAY.

40. Tan JL, Chinnaratha MA, Woodman R, Martin R, Chen HT, Carneiro G, et al. Diagnostic Accuracy of Artificial Intelligence (AI) to Detect Early Neoplasia in Barrett's Esophagus: A Non-comparative Systematic Review and Meta-Analysis. Front Med (Lausanne). 2022;9:890720.

41. Fouad YM, Mostafa I, Yehia R, EL-Khayat H. Biomarkers of Barrett's esophagus. World J Gastrointest Pathophysiol. 2014;5:450.

42. Honing J, Fitzgerald RC. Categorizing Risks within Barrett's Esophagus To Guide Surveillance and Interception; Suggesting a New Framework. Cancer Prev Res (Phila). 2023;16:313–20.

43. Mejza M, Małecka-Wojciesko E. Diagnosis and Management of Barrett's Esophagus. J Clin Med. 2023;12.

44. Robinson MD, McCarthy DJ, Smyth GK. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009;26:139–40.

45. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28:882.

46. Watts GS, Tran NL, Berens ME, Bhattacharyya AK, Nelson MA, Montgomery EA, et al. Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. Int J Cancer. 2007;121:2132–9.

47. Jabeen A, Ahmad N, Raza K. Machine Learning-based state-of-the-art methods for the classification of RNA-Seq data. In: Classification in Bioapps: Automation of Decision Making. Springer; 2018. p. 133–72.

48. Pirooznia M, Yang JY, Qu MQ, Deng Y. A comparative study of different machine learning methods on microarray gene expression data. BMC Genomics. 2008;9 SUPPL. 1.

49. Peixoto C, Lopes MB, Martins M, Casimiro S, Sobral D, Grosso AR, et al. Identification of biomarkers predictive of metastasis development in early-stage colorectal cancer using network-based regularization. BMC Bioinformatics. 2023;24.

50. MacCarthy FP, Duggan SP, Feighery R, O J, Ravi N, Kelleher D, et al. 708 IL-1B and SERPINA-3 Are Novel Markers of Aggressive Barrett's Oesophagus Phenotype Using RNA Deep Sequencing Analysis. Gastroenterology. 2014;146:S-122.

51. Maag JLV, Fisher OM, Levert-Mignon A, Kaczorowski DC, Thomas ML, Hussey DJ, et al. Novel aberrations uncovered in Barrett's esophagus and esophageal adenocarcinoma using whole transcriptome sequencing. Molecular Cancer Research. 2017;15:1558–69.

All rights reserved. No reuse allowed without permission.

52. Zhang Y, Weh KM, Howard CL, Riethoven JJ, Clarke JL, Lagisetty KH, et al. Characterizing isoform switching events in esophageal adenocarcinoma. Mol Ther Nucleic Acids. 2022;29:749–68.

53. Kimchi ET, Posner MC, Park JO, Darga TE, Kocherginsky M, Karrison T, et al. Progression of Barrett's Metaplasia to Adenocarcinoma Is Associated with the Suppression of the Transcriptional Programs of Epidermal Differentiation.

54. Ostrowski J, Mikula M, Karczmarski J, Rubel T, Wyrwicz LS, Bragoszewski P, et al. Molecular defense mechanisms of Barrett's metaplasia estimated by an integrative genomics. J Mol Med. 2007;85:733–43.

55. Stairs DB, Nakagawa H, Klein-Szanto A, Mitchell SD, Silberg DG, Tobias JW, et al. Cdx1 and c-Myc foster the initiation of transdifferentiation of the normal esophageal squamous epithelium toward Barrett's esophagus. PLoS One. 2008;3.

56. Silvers AL, Lin L, Bass AJ, Chen G, Wang Z, Thomas DG, et al. Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity. Clinical Cancer Research. 2010;16:2009–21.

57. Di Pietro M, Lao-Sirieix P, Boyle S, Cassidy A, Castillo D, Saadi A, et al. Evidence for a functional role of epigenetically regulated midcluster HOXB genes in the development of Barrett esophagus. Proc Natl Acad Sci U S A. 2012;109:9077–82.

58. Wang Q, Ma C, Kemmner W. Wdr66 is a novel marker for risk stratification and involved in epithelial-mesenchymal transition of esophageal squamous cell carcinoma. BMC Cancer. 2013;13.

59. Hyland PL, Hu N, Rotunno M, Su H, Wang C, Wang L, et al. Global changes in gene expression of Barrett's esophagus compared to normal squamous esophagus and gastric cardia tissues. PLoS One. 2014;9.

60. Cummings LC, Thota PN, Willis JE, Chen Y, Cooper GS, Furey N, et al. A nonrandomized trial of vitamin D supplementation for Barrett's esophagus. PLoS One. 2017;12.

61. Kastelein F, Biermann K, Steyerberg EW, Verheij J, Kalisvaart M, Looijenga LHJ, et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut. 2013;62:1676–83.

62. Li J, Li M han, Wang T tian, Liu X ning, Zhu X ting, Dai Y zhang, et al. SLC38A4 functions as a tumour suppressor in hepatocellular carcinoma through modulating Wnt/β-catenin/MYC/HMGCS2 axis. Br J Cancer. 2021;125:865–76.

63. Shulgin AA, Lebedev TD, Prassolov VS, Spirin P V. Plasmolipin and Its Role in Cell Processes. Mol Biol. 2021;55:773.

64. Jadhav K, Zhang Y. Activating transcription factor 3 in immune response and metabolic regulation. Liver Res. 2017;1:96–102.

65. Maag JLV, Fisher OM, Levert-Mignon A, Kaczorowski DC, Thomas ML, Hussey DJ, et al. Novel aberrations uncovered in Barrett's esophagus and esophageal adenocarcinoma using whole transcriptome sequencing. Molecular Cancer Research. 2017;15:1558–69.

66. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–96.

67. Li K, Duan P, He H, Du R, Wang Q, Gong P, et al. Construction of the Interaction Network of Hub Genes in the Progression of Barrett's Esophagus to Esophageal Adenocarcinoma. J Inflamm Res. 2023;16:1533–51.

68. Qi W, Li R, Li L, Li S, Zhang H, Tian H. Identification of key genes associated with esophageal adenocarcinoma based on bioinformatics analysis. Ann Transl Med. 2021;9:1711–1711.

All rights reserved. No reuse allowed without permission.

69. Nancarrow DJ, Clouston AD, Smithers BM, Gotley DC, Drew PA, Watson DI, et al. Whole genome expression array profiling highlights differences in mucosal defense genes in barrett's esophagus and esophageal adenocarcinoma. PLoS One. 2011;6.

70. Zhang Q, Agoston AT, Pham TH, Zhang W, Zhang X, Huo X, et al. Acidic Bile Salts Induce Epithelial to Mesenchymal Transition via VEGF Signaling in Non-Neoplastic Barrett's Cells. Gastroenterology. 2019;156:130-144.e10.

71. Yao C, Li Y, Luo L, Xiong Q, Zhong X, Xie F, et al. Identification of miRNAs and genes for predicting Barrett's esophagus progressing to esophageal adenocarcinoma using miRNA-mRNA integrated analysis. PLoS One. 2021;16.

72. Kalatskaya I. Overview of major molecular alterations during progression from Barrett's esophagus to esophageal adenocarcinoma. Ann N Y Acad Sci. 2016;1381:74–91.

73. Darlavoix T, Seelentag W, Yan P, Bachmann A, Bosman FT. Altered expression of CD44 and DKK1 in the progression of Barrett's esophagus to esophageal adenocarcinoma. Virchows Archiv. 2009;454:629–37.

74. Feith M, Stein HJ, Mueller J, Siewert JR. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53. 2004.

75. Falkenback D, Nilbert M, Öberg S, Johansson J. Prognostic value of cell adhesion in esophageal adenocarcinomas. Diseases of the Esophagus. 2008;21:97–102.

76. Paulson TG, Galipeau PC, Oman KM, Sanchez CA, Kuhner MK, Smith LP, et al. Somatic whole genome dynamics of precancer in Barrett's esophagus reveals features associated with disease progression. Nat Commun. 2022;13.

77. Pinto R, Hauge T, Jeanmougin M, Pharo HD, Kresse SH, Honne H, et al. Targeted genetic and epigenetic profiling of esophageal adenocarcinomas and non-dysplastic Barrett's esophagus. Clin Epigenetics. 2022;14.

78. Redston M, Noffsinger A, Kim A, Akarca FG, Rara M, Stapleton D, et al. Abnormal TP53 Predicts Risk of Progression in Patients With Barrett's Esophagus Regardless of a Diagnosis of Dysplasia. Gastroenterology. 2022;162:468–81.

79. Januszewicz W, Pilonis ND, Sawas T, Phillips R, O'Donovan M, Miremadi A, et al. The utility of P53 immunohistochemistry in the diagnosis of Barrett's oesophagus with indefinite for dysplasia. Histopathology. 2022;80:1081–90.

80. Kalatskaya I. Overview of major molecular alterations during progression from Barrett's esophagus to esophageal adenocarcinoma. Ann N Y Acad Sci. 2016;1381:74–91.

81. Kastelein F, Biermann K, Steyerberg EW, Verheij J, Kalisvaart M, Looijenga LHJ, et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut. 2013;62:1676–83.

82. Li S, Hoefnagel SJM, Krishnadath KK. Molecular Biology and Clinical Management of Esophageal Adenocarcinoma. Cancers 2023, Vol 15, Page 5410. 2023;15:5410.

83. Redston M, Noffsinger A, Kim A, Akarca FG, Rara M, Stapleton D, et al. Abnormal TP53 Predicts Risk of Progression in Patients With Barrett's Esophagus Regardless of a Diagnosis of Dysplasia. Gastroenterology. 2022;162:468.

84. Eluri S, Brugge WR, Daglilar ES, Jackson SA, Styn MA, Callenberg KM, et al. The presence of genetic mutations at key loci predicts progression to esophageal adenocarcinoma in Barrett's esophagus. American Journal of Gastroenterology. 2015;110:828–34.

85. Iyer PG, Codipilly DC, Chandar AK, Agarwal S, Wang KK, Leggett CL, et al. Prediction of Progression in Barrett's Esophagus Using a Tissue Systems Pathology Test: A Pooled Analysis of International Multicenter Studies. Clinical Gastroenterology and Hepatology. 2022. https://doi.org/10.1016/j.cgh.2022.02.033.

All rights reserved. No reuse allowed without permission.

86. Codipilly DC, Krishna Chandar A, Wang KK, Katzka DA, Goldblum JR, Thota PN, et al. Widearea transepithelial sampling for dysplasia detection in Barrett's esophagus: a systematic review and meta-analysis. Gastrointest Endosc. 2022;95:51-59.e7.

87. Ross-Innes CS, Chettouh H, Achilleos A, Galeano-Dalmau N, Debiram-Beecham I, MacRae S, et al. Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. Lancet Gastroenterol Hepatol. 2017;2:23–31. 88. Panda A, Bhanot G, Ganesan S, Bajpai M. Gene expression in barrett's esophagus cell lines resemble esophageal squamous cell carcinoma instead of esophageal adenocarcinoma. Cancers (Basel). 2021;13:5971.

89. Odze RD. Update on the Diagnosis and Treatment of Barrett Esophagus and Related Neoplastic Precursor Lesions. Arch Pathol Lab Med. 2007;132:1577–85.

90. Kaul V, Gross S, Corbett FS, Malik Z, Smith MS, Tofani C, et al. Clinical utility of wide-area transepithelial sampling with three-dimensional computer-assisted analysis (WATS3D) in identifying Barrett's esophagus and associated neoplasia. Diseases of the Esophagus. 2020;33.